GLP1R and diabetes mellitus: In this regard, as it has been remarked [66], the current evidence with GLP1 RAs and DPP4 inhibitors in critically ill diabetic patients with COVID-19 complications is inadequate to make therapeutic recommendations, and insulin therapy should be safely sustained as the preferred option for managing diabetes.